Rational Selection of Cyclodextrins for the Solubilization of Poorly Soluble Oral Drugs

We invite you to our next webinar:

“Rational Selection of Cyclodextrins for the Solubilization of Poorly Soluble Oral Drugs”

Poorly soluble drugs for oral administration present unique formulation challenges, particularly during early development. Formulation in a complex with cyclodextrins can be a feasible approach, but usually requires experimental screening to identify suitable combinations and amounts. To facilitate early formulation development, BASF Pharma Solutions and CycloLab have developed an application for BASF’s virtual formulation assistant ZoomLab™. Rational selection of a suitable cyclodextrin with the help of an interactive web-application is one of the key topics of this event.

REGISTRATION

Join this webinar to learn from BASF Pharma Solutions and CycloLab experts on how the virtual pharma assistant ZoomLab™ and CycloLab’s pharma grade cyclodextrins can support and streamline your formulation challenges.

3 Key Learning Objectives:

1. Attendees will learn about the various pharmaceutical cyclodextrin types as solubility and bioavailability enhancement tools to improve delivery of poorly soluble drugs.
2. Attendees will be given guidance on selection of suitable cyclodextrin excipients based on the physicochemical properties of an active ingredient.
3. Explore how a science-based web application can help you evaluate prototype cyclodextrin formulations.

Date & Time & Timezone: Nov 8, 4:00 PM CET, 10 am EST

Get more information & register here for free:

REGISTRATION

Speaker:

Dr. István Puskás, PhD

Research Chemist, CycloLab Cyclodextrin R&D Ltd.

Dr. Martin Hofsaess, PhD

R&D Scientist, BASF Pharma Solutions, Ludwigshafen, Germany

Dr. Martin Hofsaess, Scientist for digital formulation development, is a team member of BASF Development Pharma Solutions located at Ludwigshafen, Germany. In his role, Dr. Hofsaess conceptualizes and develops digital solutions for BASF’s virtual formulation assistant ZoomLabTM. The focus of his work is the digitalization of structured development approaches for enabling formulations such as amorphous solid dispersions and lipid-based formulations for solubilizing poorly soluble active pharmaceutical ingredients. Dr. Hofsaess completed his Ph.D. in pharmaceutical technology on the topic in vivo-predictive dissolution testing at the University of Frankfurt, Germany. Before his current position, he held a PostDoc position at BASF Development Pharma Solutions.